Nurix Therapeutics, Inc. NRIX Deferred offering costs
Deferred offering costs at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredOfferingCosts.
The official record: Nurix Therapeutics, Inc.’s 10-K, filed January 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s deferred offering costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s deferred offering costs?
- Nurix Therapeutics, Inc. (NRIX) reported deferred offering costs of $100K in Q3 2025.
- What does deferred offering costs mean?
- These are direct costs incurred in connection with a planned equity or debt offering that are capitalized and subsequently offset against the proceeds of the offering. Once the financing is completed, these costs are reclassified as a reduction of additional paid-in capital.